Selective Monodefluorination and Wittig Functionalization of gem-Difluoromethyl Groups to Generate Monofluoroalkenes
摘要:
Monodefluorination of gem-difluoromethyl groups is achieved using a frustrated Lewis pair (FLP) approach. Triarylphosphines and group 13 Lewis acids were surveyed as FLP components, with the combination of P(o-Tol)(3) and B(C6F5)(3) found to provide the best results, although the reaction is feasible with more economical components (PPh3 and BF3 center dot OEt2). The alpha-fluoroalkylphosphonium products arising from the reaction were of lower activity, in regard to further fluoride abstraction, as compared to difluoride starting materials, leading to highly selective monodefluorination. The activated substrates were subject to Wittig reaction protocols to generate a variety of monofluoroalkenes in moderate to high yields.
Iron-Catalyzed Difluoromethylation of Arylzincs with Difluoromethyl 2-Pyridyl Sulfone
作者:Wenjun Miao、Yanchuan Zhao、Chuanfa Ni、Bing Gao、Wei Zhang、Jinbo Hu
DOI:10.1021/jacs.7b11976
日期:2018.1.24
We report the first iron-catalyzed difluoromethylation of arylzincs with difluoromethyl2-pyridylsulfone via selective C-S bond cleavage. This method employs the readily available, bench-stable fluoroalkyl sulfone reagent and inexpensive iron catalyst, allowing facile access to structurally diverse difluoromethylated arenes at low temperatures. The experiment employing a radical clock indicates the
Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
申请人:VERTEX PHARMACEUTICALS INCORPORATED
公开号:US20160095858A1
公开(公告)日:2016-04-07
The present invention features a compound of formula I:
or a pharmaceutically acceptable salt thereof, where R
1
, R
2
, R
3
, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.
[EN] A NEW METHOD OF 18F LABELLING AND INTERMEDIATE SALTS<br/>[FR] NOUVEAU PROCÉDÉ D'ÉTIQUETAGE DE 18F ET DE SELS INTERMÉDIAIRES
申请人:NAT UNIV SINGAPORE
公开号:WO2021126080A1
公开(公告)日:2021-06-24
Disclosed herein is a salt of formula I: where R1, X, n, R, R1, Y, m, p, q, Z and o are as defined herein. Also disclosed herein are methods of using said salts in chemical synthesis, such as to prepare compounds isotopically enriched in 18F for use in PET imaging, as well as methods to make the compounds of formula I.
Frustrated Lewis-Pair-Meditated Selective Single Fluoride Substitution in Trifluoromethyl Groups
作者:Dipendu Mandal、Richa Gupta、Amit K. Jaiswal、Rowan D. Young
DOI:10.1021/jacs.9b12167
日期:2020.2.5
developed a generic protocol that allows a single substitution of one fluoride in trifluoromethylgroups with neutral phosphine and pyridine bases. The resulting phosphonium and pyridinium salts can be further functionalized via nucleophilic substitution, photoredox coupling and electrophilic transfer reactions allowing the generation of a vast array of difluoromethyl products.
HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME
申请人:EA PHARMA CO., LTD.
公开号:US20160332999A1
公开(公告)日:2016-11-17
The present invention provides a compound represented by the formula (I):
wherein each symbol is as defined in the DESCRIPTION, or a pharmaceutically acceptable salt thereof. The compound has a superior TRPA1 antagonist activity, and can provide a medicament useful for the prophylaxis or treatment of diseases involving TRPA1 antagonist and TRPA1.